| Literature DB >> 34068174 |
Sofie Van Den Broucke1, Jeroen A J Vanoirbeek2, Rita Derua3, Peter H M Hoet1,2, Manosij Ghosh1,2.
Abstract
Via inhalation we are continuously exposed to environmental and occupational irritants which can induce adverse health effects, such as irritant-induced asthma (IIA). The airway epithelium forms the first barrier encountered by these agents. We investigated the effect of environmental and occupational irritants on the airway epithelial barrier in vitro. The airway epithelial barrier was mimicked using a coculture model, consisting of bronchial epithelial cells (16HBE) and monocytes (THP-1) seeded on the apical side of a permeable support, and human lung microvascular endothelial cells (HLMVEC) grown on the basal side. Upon exposure to graphene (G) and graphene oxide (GO) in a suspension with fetal calf serum (FCS), ammonium persulfate (AP), sodium persulfate (SP) and hypochlorite (ClO-), the transepithelial electrical resistance (TEER) and flux of fluorescent labelled dextran (FD4-flux), was determined. Exposure to graphene nanoparticles (GNPs) induced an immediate negative effect on the epithelial barrier, whereas ClO- only had a negative impact after 24 h of exposure. AP and SP did not affect the barrier properties. The tight junctions (TJ) network showed less connected zonula occludens 1 (ZO-1) and occludin staining in GNP-exposed cocultures. Functional analysis of the phosphoproteomic data indicated that proteins in the adherens junction (AJ) and TJ pathways showed an altered phosphorylation due to GNP exposure. To conclude, the negative effect of GNPs on the epithelial barrier can be explained by the slightly altered the TJ organization which could be caused by alterations in the phosphorylation level of proteins in the AJ and TJ pathway.Entities:
Keywords: adherens junction; barrier integrity; graphene nanoparticles; phosphoproteomics; tight junction
Year: 2021 PMID: 34068174 PMCID: PMC8152977 DOI: 10.3390/nano11051283
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Characterization of G and GO NPs—Raman spectrum provided from the manufacturer of (a) G and (c) GO. Representative transmission electron spectroscopy (TEM) images of (b) G and (d) GO.
Figure 2WST-1 and LDH assays of 16HBE cells exposed to G, GO, AP, SP and ClO−—the 16HBE cells were exposed to increasing concentrations of the agents for 24 h. Afterwards, the cell viability was evaluated using the WST-1 and LDH assay. Mean ± SD, n = 2–3, each experiment was performed in triplicate. * p < 0.05 (t-test).
Figure 3TEER measurements of cocultures exposed to G, GO, AP, SP and ClO−—the TEER values are normalized and represented as percentages of the baseline value. Significant different at * all time points, at # some time points and at ° 24 h after the start of exposure compared to the vehicle control. p < 0.001: 3 symbols. Mean ± SD, n = 3–7, each experiment was performed in duplicate.
Figure 4FITC-dextran transport (a) and TEER (b) of cocultures exposed to G, GO, SP, AP and ClO−—** p < 0.01, *** p < 0.001 compared to the vehicle control. Mean ± SD, n = 3–8; each experiment was performed in duplicate.
Figure 5Immunofluorescent staining of TJ in cocultures exposed to G and GO suspended using 0.2% FCS. Representative images from cocultures apically exposed to vehicle, 128 µg/mL graphene and 128 µg/mL graphene oxide suspended using 0.2% FCS. Immunofluorescent staining for Occludin (red) and ZO-1 (green), cell nuclei were counterstained with DAPI (blue).
Functional classification of the differentially phosphorylated proteins by graphene exposure (fold change ≥ 1.5 or ≤ 0.5). Fifteen of the enriched pathways had a p-value < 0.05. The table lists the top 5 out of these enriched pathways.
| No. | Full Gene Name | Gene ID | Enrichment | FDR | |
|---|---|---|---|---|---|
| Spliceosome | 6.92 × 10−13 | 10.28 | 8.15 × 10−10 | ||
| 1 | Apoptotic chromatin condensation inducer 1 | ACIN1 | |||
| 2 | Calcium homeostasis endoplasmic reticulum protein | CHERP | |||
| 3 | DEAH-box helicase 16 | DHX16 | |||
| 4 | Heterogeneous nuclear ribonucleoprotein C (C1/C2) | HNRNPC | |||
| 5 | Heterogeneous nuclear ribonucleoprotein K | HNRNPK | |||
| 6 | Pre-mRNA processing factor 38A | PRPF38A | |||
| 7 | RNA binding motif protein 17 | RBM17 | |||
| 8 | RNA binding motif protein 8A | RBM8A | |||
| 9 | X-linked RNA binding motif protein X-linked | RBMX | |||
| 10 | Squamous cell carcinoma antigen recognized by T-cells 1 | SART1 | |||
| 11 | Small nuclear ribonucleoprotein U5 subunit 200 | SNRNP200 | |||
| 12 | Serine and arginine rich splicing factor 4 | SRSF4 | |||
| 13 | Serine and arginine rich splicing factor 6 | SRSF6 | |||
| 14 | Serine and arginine rich splicing factor 9 | SRSF9 | |||
| 15 | THO complex 2 | THOC2 | |||
| 16 | Transformer 2 alpha homolog | TRA2A | |||
| 17 | Transformer 2 beta homolog | TRA2B | |||
| 18 | Ubiquitin specific peptidase 39 | USP39 | |||
|
|
|
|
| ||
| 1 | Catenin alpha 1 | CTNNA1 | |||
| 2 | Catenin alpha 2 | CTNNA2 | |||
| 3 | Catenin beta 1 | CTNNB1 | |||
| 4 | Catenin delta 1 | CTNND1 | |||
| 5 | Epidermal growth factor receptor | EGFR | |||
| 6 | Lim domain 7 | LMO7 | |||
| 7 | Nectin cell adhesion molecule 1 | NECTIN1 | |||
| 8 | Tight junction protein 1 | TJP1 | |||
|
|
|
|
| ||
| 1 | Apoptotic chromatin condensation inducer 1 | ACIN1 | |||
| 2 | FMR1 autosomal homolog 2 | FXR2 | |||
| 3 | Nucleoporin 88 | NUP88 | |||
| 4 | Nucleoporin 93 | NUP93 | |||
| 5 | Nucleoporin 98 | NUP98 | |||
| 6 | Pinin desmosome associated protein | PNN | |||
| 7 | RNA binding motif protein 8A | RBM8A | |||
| 8 | Serine and arginine repetitive matrix 1 | SRRM1 | |||
| 9 | THO complex 2 | THOC2 | |||
| 10 | THO complex 5 | THOC5 | |||
|
|
|
|
| ||
| 1 | Dyskerin pseudouridine synthase 1 | DKC1 | |||
| 2 | NOP56 ribonucleoprotein | NOP56 | |||
| 3 | NOP58 ribonucleoprotein | NOP58 | |||
| 4 | Treacle ribosome biogenesis factor 1(TCOF1) | TCOF1 | |||
| 5 | UTP 14 small subunit processome component | UTP14A | |||
| 6 | UTP 18 small subunit processome component 18 | UTP18 | |||
| 7 | 5′-3′ exoribonuclease 2 | XRN2 | |||
|
|
|
|
| ||
| 1 | Claudin 3 | CLDN3 | |||
| 2 | Catenin alpha 1 | CTNNA1 | |||
| 3 | Catenin alpha 2 | CTNNA2 | |||
| 4 | Catenin beta 1 | CTNNB1 | |||
| 5 | Cortactin | CTTN | |||
| 6 | Crumbs cell polarity complex component | PATJ | |||
| 7 | Tight junction protein 1 | TJP1 | |||
| 8 | Tight junction protein 2 | TJP2 |
Functional classification of differentially phosphorylated proteins by graphene oxide exposure (fold change ≥ 1.5 or ≤ 0.5). Seventeen of the enriched pathways had a p-value < 0.05. The table lists the top 5 out of these enriched pathways.
| No. | Full Gene Name | Gene ID | Enrichment | FDR | |
|---|---|---|---|---|---|
| Spliceosome | 1.75 × 10−12 | 9.74 | 2.08 × 10−9 | ||
| 1 | Apoptotic chromatin condensation inducer 1 | ACIN1 | |||
| 2 | Calcium homeostasis endoplasmic reticulum protein | CHERP | |||
| 3 | DEAH-box helicase 16 | DHX16 | |||
| 4 | Heterogeneous nuclear ribonucleoprotein C (C1/C2) | HNRNPC | |||
| 5 | Heterogeneous nuclear ribonucleoprotein K | HNRNPK | |||
| 6 | Pre-mRNA processing factor 38A | PRPF38A | |||
| 7 | RNA binding motif protein 8A | RBM8A | |||
| 8 | X-linked RNA binding motif protein X-linked | RBMX | |||
| 9 | Squamous cell carcinoma antigen recognized by T-cells 1 | SART1 | |||
| 10 | Small nuclear ribonucleoprotein U5 subunit 200 | SNRNP200 | |||
| 11 | Serine and arginine rich splicing factor 10 | SRSF10 | |||
| 12 | Serine and arginine rich splicing factor 4 | SRSF4 | |||
| 13 | Serine and arginine rich splicing factor 6 | SRSF6 | |||
| 14 | Serine and arginine rich splicing factor 9 | SRSF9 | |||
| 15 | THO complex 2 | THOC2 | |||
| 16 | Transformer 2 alpha homolog | TRA2A | |||
| 17 | Transformer 2 beta homolog | TRA2B | |||
| 18 | Ubiquitin specific peptidase 39 | USP39 | |||
|
|
|
|
| ||
| 1 | Claudin 3 | CLDN3 | |||
| 2 | Claudin 4 | CLDN4 | |||
| 3 | Claudin 6 | CLDN6 | |||
| 4 | Catenin alpha 1 | CTNNA1 | |||
| 5 | Catenin alpha 2 | CTNNA2 | |||
| 6 | Catenin beta 1 | CTNNB1 | |||
| 7 | Cortactin | CTTN | |||
| 8 | Crumbs cell polarity complex component | PATJ | |||
| 9 | Tight junction protein 1 | TJP1 | |||
| 10 | Tight junction protein 2 | TJP2 | |||
|
|
|
|
| ||
| 1 | Catenin alpha 1 | CTNNA1 | |||
| 2 | Catenin alpha 2 | CTNNA2 | |||
| 3 | Catenin beta 1 | CTNNB1 | |||
| 4 | Catenin delta 1 | CTNND1 | |||
| 5 | Epidermal growth factor receptor | EGFR | |||
| 6 | Nectin cell adhesion molecule 1 | NECTIN1 | |||
| 7 | Tight junction protein 1 | TJP1 | |||
|
|
|
|
| ||
| 1 | Apoptotic chromatin condensation inducer 1 | ACIN1 | |||
| 2 | Eukaryotic translation initiation factor 5B | EIF5B | |||
| 3 | FMR1 autosomal homolog 2 | FXR2 | |||
| 4 | Nucleoporin 93 | NUP93 | |||
| 5 | Nucleoporin 98 | NUP98 | |||
| 6 | Pinin desmosome associated protein | PNN | |||
| 7 | RNA binding motif protein 8A | RBM8A | |||
| 8 | Serine and arginine repetitive matrix 1 | SRRM1 | |||
| 9 | THO complex 2 | THOC2 | |||
| 10 | THO complex 5 | THOC5 | |||
|
|
|
|
| ||
| 1 | Claudin 3 | CLDN3 | |||
| 2 | Claudin 4 | CLDN4 | |||
| 3 | Claudin 6 | CLDN6 | |||
| 4 | Major histocompatibility complex class I A | HLA-A | |||
| 5 | Major histocompatibility complex class I B | HLA-B | |||
| 6 | Major histocompatibility complex class I C | HLA-C | |||
| 7 | L1 cell adhesion molecule | L1CAM | |||
| 8 | Myelin protein zero like 1 | MPZL1 | |||
| 9 | Nectin cell adhesion molecule 1 | NECTIN1 |
Figure 6Overview of differentially phosphorylated proteins in TJ and AJ pathways—the proteins that were differently phosphorylated due to exposure to G, GO or both GNPs are depicted, respectively, in yellow, blue or green boxes. Proteins that were unaffected are depicted in white boxes. The orange hexagons represent protein kinases or phosphatases. ‘+P’ and ‘−P’ indicate, respectively, phosphorylation and de-phosphorylation; if this activates the function of the targeted protein a green arrow is drawn, if this inhibits the function of the targeted protein a red arrow is drawn. RPTP, receptor protein tyrosine phosphatase; PTP, protein tyrosine phosphatase; RTPK, receptor protein tyrosine kinase; PTK, protein tyrosine kinase. The figure is a simplified and combined version of the TJ and AJ pathway from the KEGG database.